lofexidine sold brand name lucemyra among medication historically used treat high blood pressure today commonly used help physical symptoms opioid taken adrenergic receptor approved use food drug administration united states us food drug administration fda considers firstinclass united states brand name lucemyra lofexidine hcl approved mitigation withdrawal symptoms facilitate abrupt discontinuation opioids adults treatment duration united kingdom lofexidine commonly used conjunction opioid receptor antagonist naltrexone rapid detoxification cases two drugs paired naltrexone administered induce opioidreceptor blockade sending subject immediate withdrawal accelerating detoxification process lofexidine given relieve symptoms associated withdrawal including chills sweating stomach cramps muscle pain runny nosecitation needed united kingdoms national institute health care excellence nice guidelines recommend use methadone buprenorphine firstline agents management opioid use disorder however lofexidine considered acceptable alternative people mild uncertain opioid dependence need shortterm lofexidine eliminate symptoms opioid withdrawal reduces indeed one suggested use lofexidine ease withdrawal symptoms methadone dependence use approved united states possibility using lofexidine treat alcohol withdrawal symptoms investigated yet shown effective also used treatment cases postmenopausal hot flashes lofexidines safety pregnancy setting breastfeeding caution warranted chronic kidney impairment adverse effects occurred taking lofexidine include addition people may experience sudden jump blood pressure stopping lofexidine mgkg animals studies highdose single administrations lofexidine proved tolerable animals repeat administration induced symptoms consistent toxicity studies mice rats dogs included ataxia somnolence tremors expected overdose lofexidine would result symptoms akin pharmacological side effects humans bradycardia many drugdrug interactions lofexidine lofexidine prolongs qt interval result severe interaction torsade de pointes combined drugs also prolong qt interval patientspecific characteristics increase risk clinically significant drugdrug interaction result many qtprolonging drugs may interact lofexidine include medications methadone amiodarone citalopram fluconazole medications may increase risk low level potassium blood thereby indirectly increasing risk qt prolongation example dexamethasone hydrochlorothiazide theophylline lower level potassium lofexidine depress central nervous system cns combination cns depressants may reduce persons ability perform tasks require skills attention example clobazam gabapentin levetiracetam depress risk hypotension low blood pressure increased lofexidine combined drugs lower blood pressure may include losartan metoprolol lofexidine agonist adrenergic receptor subtypes highest activity ki represents dissociation lofexidines binding specific subtype receptor smaller ki value stronger drug binds receptor exert activity lofexidine inhibits release norepinephrine central peripheral nervous system thereby reducing symptoms opioid withdrawal documented effect drug craving endogenous opioid lofexidines oral bioavailability extensive oral absorption peak plasma concentrations occur hours single administration halflife hours lofexidine extensively metabolized liver primarily cleared kidney plasma protein lofexidine exists solid room temperature melting point degrees pair ortho chlorine atoms phenyl ring necessary lofexidines agonism adrenergic receptor subtype removal either chlorine atom results antagonism lofexidine structurally analogous clonidine another adrenergic receptor agonist used treatment opioid withdrawal symptoms comparison two structures shown right contain imidazoline ring phenyl ring differences structure shown red similarities black addition structural differences administration lofexidine people abuse opioids shown effective longer duration fewer withdrawal symptoms clonidine even one however clonidine often preferred substantially cheaper lofexidine purchased private nonnhs prescription factor exacerbated considerable number quantities medications prescribed alleviate constellation withdrawal signs symptoms additionally clonidine shown significantly lower blood pressure therefore although similar lofexidine clonidine frequently prescribed treat high blood pressurecitation needed britannia pharmaceuticals licensed lofexidine sold us worldmeds sale north united kingdom hydrochloride form lofexidine hcl licensed sold since opioid withdrawal relief tablet form britlofex britannia britlofex available prescription lofexidine first approved us fda may brand name lucemyra produced us noted first nonopioid drug approved us treatment opioid httpsenwikipediaorgwikilofexidine